Michael Kilbourn
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Kilbourn.
Brain | 2010
Nicolaas I. Bohnen; Martijn Muller; Vikas Kotagal; Robert A. Koeppe; Michael Kilbourn; Roger L. Albin; Kirk A. Frey
Olfactory dysfunction is common in subjects with Parkinson’s disease. The pathophysiology of such dysfunction, however, remains poorly understood. Neurodegeneration within central regions involved in odour perception may contribute to olfactory dysfunction in Parkinson’s disease. Central cholinergic deficits occur in Parkinson’s disease and cholinergic neurons innervate regions, such as the limbic archicortex, involved in odour perception. We investigated the relationship between performance on an odour identification task and forebrain cholinergic denervation in Parkinson’s disease subjects without dementia. Fifty-eight patients with Parkinson’s disease (mean Hoehn and Yahr stage 2.5 ± 0.5) without dementia (mean Mini-Mental State Examination, 29.0 ± 1.4) underwent a clinical assessment, [11C]methyl-4-piperidinyl propionate acetylcholinesterase brain positron emission tomography and olfactory testing with the University of Pennsylvania Smell Identification Test. The diagnosis of Parkinson’s disease was confirmed by [11C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission tomography. We found that odour identification test scores correlated positively with acetylcholinesterase activity in the hippocampal formation (r = 0.56, P < 0.0001), amygdala (r = 0.50, P < 0.0001) and neocortex (r = 0.46, P = 0.0003). Striatal monoaminergic activity correlated positively with odour identification scores (r = 0.30, P < 0.05). Multiple regression analysis including limbic (hippocampal and amygdala) and neocortical acetylcholinesterase activity as well as striatal monoaminergic activity, using odour identification scores as the dependent variable, demonstrated a significant regressor effect for limbic acetylcholinesterase activity (F = 10.1, P < 0.0001), borderline for striatal monoaminergic activity (F = 1.6, P = 0.13), but not significant for cortical acetylcholinesterase activity (F = 0.3, P = 0.75). Odour identification scores correlated positively with scores on cognitive measures of episodic verbal learning (r = 0.30, P < 0.05). These findings indicate that cholinergic denervation of the limbic archicortex is a more robust determinant of hyposmia than nigrostriatal dopaminergic denervation in subjects with moderately severe Parkinsons disease. Greater deficits in odour identification may identify patients with Parkinsons disease at risk for clinically significant cognitive impairment.
Journal of Cerebral Blood Flow and Metabolism | 2008
Roger L. Albin; Robert A. Koeppe; Nicolaas I. Bohnen; K. Wernette; Michael Kilbourn; Kirk A. Frey
Postmortem data indicate loss of serotoninergic neurons in Parkinsons disease (PD). We used the serotonin transporter (SERT) radioligand 3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitril (DASB) and positron emission tomography to examine SERT distribution and changes in early PD subjects. We studied five PD subjects (H&Y 1 to 2.5) and eight normal controls. There is reduced SERT binding in PD. The magnitude of DASB binding reductions was greater in the forebrain than in the brainstem regions. There was no asymmetry of diminished SERT binding. DASB binding in the medulla was relatively spared, inconsistent with the description of early prominent pathologic study in these caudal brainstem nuclei.
Society of Nuclear Medicine Annual Meeting Abstracts | 2012
Nicolaas I. Bohnen; Martijn Muller; Vikas Kotagal; Robert A. Koeppe; Michael Kilbourn; Roger L. Albin; Kirk A. Frey
Society of Nuclear Medicine Annual Meeting Abstracts | 2012
Myria Petrou; Robert A. Koeppe; Peter Scott; Nicolaas I. Bohnen; Michael Kilbourn; Kirk A. Frey
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Kirk A. Frey; Robert A. Koeppe; Michael Kilbourn; Raj Manchanda; Michael J. Pontecorvo; Daniel Skovronsky
Society of Nuclear Medicine Annual Meeting Abstracts | 2009
Nicolaas I. Bohnen; Martijn Muller; Robert A. Koeppe; Michael Kilbourn; Kirk A. Frey; Roger L. Albin
Society of Nuclear Medicine Annual Meeting Abstracts | 2013
Michael Kilbourn; Allen F. Brooks; Keunsam Jang; Adam C. Runkle; Ryan Littich; Xia Shao; Peter Scott
Society of Nuclear Medicine Annual Meeting Abstracts | 2013
Melissa E. Rodnick; Xia Shao; Kenneth M. Kozloff; Phillip Sherman; Peter Scott; Michael Kilbourn
Society of Nuclear Medicine Annual Meeting Abstracts | 2012
Garrett M. Carpenter; Xia Shao; Timothy J. Desmond; Phillip Sherman; Carole A. Quesada; Michael Kilbourn; Peter Scott
Society of Nuclear Medicine Annual Meeting Abstracts | 2010
Martijn Muller; Roger L. Albin; Robert A. Koeppe; Michael Kilbourn; Kirk A. Frey; Nicolaas I. Bohnen